5.92
Precedente Chiudi:
$5.80
Aprire:
$5.86
Volume 24 ore:
87,901
Relative Volume:
0.43
Capitalizzazione di mercato:
$243.24M
Reddito:
$31.37M
Utile/perdita netta:
$-53.77M
Rapporto P/E:
-4.0724
EPS:
-1.4537
Flusso di cassa netto:
$-49.02M
1 W Prestazione:
-2.07%
1M Prestazione:
+1.37%
6M Prestazione:
-13.95%
1 anno Prestazione:
-68.41%
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Nome
Silence Therapeutics Plc Adr
Settore
Industria
Telefono
44-0-20-3457 6900
Indirizzo
72 HAMMERSMITH ROAD, LONDON
Confronta SLN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SLN
Silence Therapeutics Plc Adr
|
5.92 | 243.24M | 31.37M | -53.77M | -49.02M | -1.4537 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-11 | Iniziato | Goldman | Sell |
2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
2024-09-03 | Iniziato | Jefferies | Buy |
2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Borsa (SLN) Ultime notizie
H.C. Wainwright reiterates buy rating on Silence Therapeutics stock By Investing.com - Investing.com South Africa
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - MSN
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year By Investing.com - Investing.com India
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics stock hits 52-week low at $3.19 By Investing.com - Investing.com South Africa
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - MSN
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn - Investing.com
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn By Investing.com - Investing.com South Africa
Taiwan Semiconductor Valuation: How Realistic Is the Price? - The Globe and Mail
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges - Investing.com
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Goldman Sachs cuts Silence Therapeutics stock rating to Sell By Investing.com - Investing.com South Africa
Should investors be concerned about Silence Therapeutics Plc ADR (SLN)? - US Post News
Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex
Cloudflare Inc’s (NET) Stock: A 29.10% Simple Moving Average for the Past 20 Days - The News Heater
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. WAINWRIGHT MAINTAINS $75 TARGET ON SILENCE THERAPEUTICS STOCK By Investing.com - Investing.com South Africa
European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Silence Therapeutics' SWOT analysis: stock's potential in RNAi therapeutics - Investing.com
Silence Therapeutics announces additional results from SANRECO study - TipRanks
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Yahoo Finance
Top 3 Health Care Stocks You'll Regret Missing In Q4Amarin Corp (NASDAQ:AMRN) - Benzinga
Zerlasiran shows promise in phase 2 study for cardiovascular risk - Investing.com India
Silence Therapeutics to Join Guggenheim Biotech Conference By Investing.com - Investing.com India
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? - Nasdaq
Claire Keast-Butler - Cooley
Our approach to nucleotide-based therapeutics - AstraZeneca
5 Stocks to Buy as the Drug Industry Bets Big on Innovation - Nasdaq
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Genfit (NASDAQ:GNFT) Stock Quotes, Forecast and News Summary - Benzinga
Silence Therapeutics (SLN) Stock Price, News & Analysis - MarketBeat
Silence Therapeutics (SLN) - Zacks Investment Research
Silence Therapeutics Plc Adr Azioni (SLN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):